

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

**Pr TARO-DICLOFENAC**

Diclofenac Sodium Topical Solution

Solution, 1.5% w/w, Topical

USP

Non-Steroidal Anti-Inflammatory Drug (NSAID)

Taro Pharmaceuticals Inc.  
130 East Drive  
Brampton, Ontario  
L6T 1C1

Date of Initial Authorization:  
February 21, 2014

Date of Revision:  
April 5, 2023

Submission Control Number: 263167

## RECENT MAJOR LABEL CHANGES

|  |         |
|--|---------|
| <a href="#">3 Serious Warnings and Precautions</a> | 04/2023 |
| <a href="#">7 Warnings and Precautions</a>         | 04/2023 |

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

|   |           |
|---|-----------|
| <b>RECENT MAJOR LABEL CHANGES .....</b>                           | <b>2</b>  |
| <b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>               | <b>4</b>  |
| <b>1 INDICATIONS .....</b>  | <b>4</b>  |
| 1.1 Pediatrics (<18 years of age) .....                           | 4         |
| 1.2 Geriatrics (≥65 years of age).....                            | 4         |
| <b>2 CONTRAINDICATIONS.....</b>                                   | <b>4</b>  |
| <b>3 SERIOUS WARNINGS AND PRECAUTIONS BOX.....</b>                | <b>5</b>  |
| <b>4 DOSAGE AND ADMINISTRATION.....</b>                           | <b>6</b>  |
| 4.1 Dosing Considerations.....                                    | 6         |
| 4.2 Recommended Dose and Dosage Adjustment.....                   | 6         |
| 4.4 Administration.....   | 6         |
| 4.5 Missed Dose .....   | 7         |
| <b>5 OVERDOSAGE .....</b>   | <b>7</b>  |
| <b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .....</b> | <b>8</b>  |
| <b>7 WARNINGS AND PRECAUTIONS.....</b>                            | <b>8</b>  |
| 7.1 Special Populations .....                                     | 14        |
| 7.1.1 Pregnant Women .....  | 14        |
| 7.1.2 Breast-feeding .....  | 15        |
| 7.1.3 Pediatrics .....  | 15        |
| 7.1.4 Geriatrics.....   | 15        |
| <b>8 ADVERSE REACTIONS .....</b>                                  | <b>15</b> |
| 8.1 Adverse Reaction Overview .....                               | 15        |
| 8.2 Clinical Trial Adverse Reactions.....                         | 16        |
| 8.3 Less Common Clinical Trial Adverse Reactions .....            | 17        |
| 8.5 Post-Market Adverse Reactions .....                           | 17        |
| <b>9 DRUG INTERACTIONS .....</b>                                  | <b>18</b> |
| 9.2 Drug Interactions Overview .....                              | 18        |

|   |   |           |
|---|---|-----------|
| 9.3   | Drug-Behavioural Interaction .....          | 18        |
| 9.4   | Drug-Drug Interactions .....                | 18        |
| 9.5   | Drug-Food Interactions.....                 | 19        |
| 9.6   | Drug-Herb Interactions .....                | 20        |
| 9.7   | Drug-Laboratory Test Interactions.....      | 20        |
| <b>10</b>                                   | <b>CLINICAL PHARMACOLOGY.....</b>           | <b>20</b> |
| 10.1  | Mechanism of Action .....                   | 20        |
| 10.2  | Pharmacodynamics .....                      | 20        |
| 10.3  | Pharmacokinetics .....                      | 20        |
| <b>11</b>                                   | <b>STORAGE, STABILITY AND DISPOSAL.....</b> | <b>22</b> |
| <b>12</b>                                   | <b>SPECIAL HANDLING INSTRUCTIONS.....</b>   | <b>22</b> |
| <b>PART II: SCIENTIFIC INFORMATION.....</b> |   | <b>23</b> |
| <b>13</b>                                   | <b>PHARMACEUTICAL INFORMATION.....</b>      | <b>23</b> |
| <b>14</b>                                   | <b>CLINICAL TRIALS .....</b>                | <b>24</b> |
| 14.1  | Clinical Trials by Indication .....         | 24        |
| <b>15</b>                                   | <b>MICROBIOLOGY .....</b>                   | <b>28</b> |
| <b>16</b>                                   | <b>NON-CLINICAL TOXICOLOGY .....</b>        | <b>28</b> |
| <b>17</b>                                   | <b>SUPPORTING PRODUCT MONOGRAPHS .....</b>  | <b>31</b> |
| <b>PATIENT MEDICATION INFORMATION.....</b>  |   | <b>32</b> |

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

TARO-DICLOFENAC (diclofenac sodium solution) is indicated for the treatment of the symptoms associated with osteoarthritis of the knee(s), only for a treatment regimen of not more than three months in duration, whether continuous or intermittent.

#### 1.1 Pediatrics (<18 years of age)

No data are available to Health Canada, therefore TARO-DICLOFENAC is contraindicated for pediatric patients. See [2 CONTRAINDICATIONS](#).

#### 1.2 Geriatrics (≥65 years of age)

Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety. See [7 WARNINGS AND PRECAUTIONS](#) and [4.2 Recommended Dose and Dosage Adjustment](#).

### 2 CONTRAINDICATIONS

TARO-DICLOFENAC (diclofenac sodium solution) is contraindicated in:

- The peri-operative setting of coronary artery bypass graft surgery (CABG). Although diclofenac sodium solution has NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications.
- Patients who are hypersensitive to this drug or to other non-steroidal anti-inflammatory drug (NSAID), or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#). The potential for cross-reactivity between different NSAIDs must be kept in mind.
- Patients who are pregnant (all trimesters).
- Patients who are breastfeeding as the safety of diclofenac sodium solution has not been established in this group.
- Pediatric patients less than 18 years of age as the safety of diclofenac sodium solution has not been established in this group.
- Patients with severe uncontrolled heart failure.
- Patients with active peptic ulcer, a history of recurrent ulceration or active inflammatory disease of the gastrointestinal system.
- Patients with the complete or partial syndrome of acetylsalicylic acid (ASA) intolerance (rhinosinusitis, urticaria/angioedema, nasal polyps and asthma), in whom asthma, anaphylaxis, urticaria, rhinitis or other allergic manifestations are precipitated by ASA or other non-steroidal anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at

risk of a severe reaction even if they have taken NSAIDs in the past without any adverse effects. See [7 WARNING AND PRECAUTIONS](#), Sensitivity/resistance.

- Patients with severe hepatic impairment or active liver disease.
- Patients with severely impaired or deteriorating renal function (creatinine clearance <30 mL/min). Individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored. See [7 WARNINGS AND PRECAUTIONS, Renal](#).
- Known hyperkalemia. See [7 WARNINGS AND PRECAUTIONS, Renal](#).
- Patients using other NSAIDs because of the absence of any evidence demonstrating synergistic benefits and the potential for additive side effects.
- A treatment regimen of duration longer than 3 months, because the long term safety of diclofenac sodium solution is unknown.

### 3 SERIOUS WARNINGS AND PRECAUTIONS BOX

#### Serious Warnings and Precautions

- **Risk of Cardiovascular (CV) Adverse Events: Ischemic Heart Disease, Cerebrovascular Disease, Congestive Heart Failure (NYHA II-IV):**

TARO-DICLOFENAC is a non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. The risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

Caution should be exercised in prescribing TARO-DICLOFENAC to any patient with ischemic heart disease (including but NOT limited to acute myocardial infarction, history of myocardial infarction and/or angina), cerebrovascular disease (including but NOT limited to stroke, cerebrovascular accident, transient ischemic attacks and/or amaurosis fugax) and/or congestive heart failure (NYHA II-IV).

Use of NSAIDs, such as TARO-DICLOFENAC, can promote sodium retention in a dose-dependent manner, through a renal mechanism, which can result in increased blood pressure and/or exacerbation of congestive heart failure.

Therefore, caution should be exercised when prescribing TARO-DICLOFENAC . See [7 WARNINGS AND PRECAUTIONS](#), Cardiovascular.

- **Risk of Gastrointestinal (GI) Adverse Events**

Use of NSAIDs, such as TARO-DICLOFENAC, is associated with an increased incidence of gastrointestinal adverse events (such as ulceration, bleeding, perforation and obstruction of the upper and lower gastrointestinal tract). See [7 WARNINGS AND PRECAUTIONS](#), Gastrointestinal.

- **Risk in Pregnancy:**

TARO-DICLOFENAC is CONTRAINDICATED for use in women who are pregnant (all trimesters). See [2 CONTRAINDICATIONS](#).

## 4 DOSAGE AND ADMINISTRATION

### 4.1 Dosing Considerations

- For patients older than 65 years and frail or debilitated see [4.2 Recommended Dose and Dosage Adjustment](#).
- Because the long-term safety of TARO-DICLOFENAC is unknown, TARO-DICLOFENAC is indicated for a treatment regimen of not more than three months in duration, whether continuous or intermittent.
- TARO-DICLOFENAC therapy should be discontinued if the application site displays signs of significant skin reaction, including swelling, urticaria or vesiculobullous rash.

### 4.2 Recommended Dose and Dosage Adjustment

**Table 1 – Dosage and Administration of TARO-DICLOFENAC (1.5% w/w diclofenac sodium solution)**

| Medical Condition             | Population (Age Group)           | Dose  | Route of Administration | Maximum Duration of Treatment |
|-------------------------------|----------------------------------|---|-------------------------|-------------------------------|
| Osteoarthritis of the knee(s) | Adults ( $\geq 18$ years of age) | 50 drops per knee, 3 times a day, or 40 drops per knee, 4 times a day | Topical                 | 3 months                      |

**Pediatrics (<18 years of age):** No data are available to Health Canada, therefore TARO-DICLOFENAC is contraindicated for pediatric patients.

**Geriatrics ( $\geq 65$  years of age):** Patients older than 65 years and frail or debilitated patients are most susceptible to a variety of adverse reactions from non-steroidal anti-inflammatory drugs (NSAIDs); the incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. Most reports of fatal GI events are in this population. Older patients are also at risk of lower esophageal ulceration and bleeding.

For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision. See [WARNINGS AND PRECAUTIONS, Renal](#).

### 4.4 Administration

TARO-DICLOFENAC is intended for **external use only**. Contact with the eyes or mucous membranes should be avoided.

TARO-DICLOFENAC should be applied to clean, dry skin, and not used under bandages or dressings.

TARO-DICLOFENAC should be dispensed onto the hand, or directly onto the knee, and spread evenly around front, back and sides of the knee until completely covered.

TARO-DICLOFENAC treatment has no relationship to food intake.

The treatment regimen for TARO-DICLOFENAC should not exceed three months in duration, whether continuous or intermittent.

#### **4.5 Missed Dose**

If one or more doses are missed, the next scheduled dose should be applied. Two doses of TARO-DICLOFENAC should not be applied to make up for a forgotten dose.

### **5 OVERDOSAGE**

In the event of ingestion of TARO-DICLOFENAC (1.5% w/w diclofenac sodium in 45% dimethyl sulfoxide), there is no specific antidote. An entire 60 mL bottle of TARO-DICLOFENAC contains approximately 960 mg of diclofenac sodium. Systemic absorption should be prevented as soon as possible by the induction of vomiting, gastric lavage or treatment with activated charcoal. Supportive and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal irritation and respiratory depression. Measures to accelerate elimination (e.g., forced diuresis, hemoperfusion, and dialysis) may be considered, but may be of limited use because of the high protein binding and extensive metabolism of diclofenac.

A 60 mL bottle of TARO-DICLOFENAC contains approximately 29 g of dimethyl sulfoxide (DMSO), well below any toxic level (oral LD<sub>50</sub> of DMSO in monkeys is >4 g/kg, while dermal LD<sub>50</sub> in monkeys is >11 g/kg). Acute toxicity through inhalation of high vapour concentrations of DMSO, through the use or abuse of diclofenac sodium solution, is remote. In the event that exposure occurs, it may lead to irritation of the mucous membranes of the upper respiratory tract, wheezing, nausea or vomiting. Treatment includes administration of oxygen or other symptomatic measures as necessary.

In the event of topical application of an excessive dose, wash the area with soap and water as soon as possible. Local irritation may occur. Treatment includes symptomatic measures as necessary.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 2 – Dosage Forms, Strengths, Composition and Packaging

| Route of Administration | Dosage Form / Strength/Composition        | Non-medicinal Ingredients   |
|-------------------------|---|---|
| Topical                 | Solution<br>1.5% w/w of diclofenac sodium | dimethyl sulfoxide, ethanol, glycerin and propylene glycol and purified water |

TARO-DICLOFENAC (diclofenac sodium solution) is a clear, colourless to slightly pink-orange, odourless liquid, which contains diclofenac sodium 1.5% w/w in a solution base consisting of dimethyl sulfoxide, glycerin, propylene glycol, ethanol and purified water. It is supplied in high-density polyethylene bottles of 60 and 150 mL with a plastic dropper cap.

## 7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

### Carcinogenesis and Mutagenesis

See [16 NON-CLINICAL TOXICOLOGY](#).

### Cardiovascular

**TARO-DICLOFENAC is a non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. Large population-based observational studies, meta-analyses and systematic reviews suggest an increased risk of myocardial infarction and stroke also in association with the use of diclofenac. The risk may increase with the dose and duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.**

**Caution should be exercised in prescribing TARO-DICLOFENAC to patients with risk factors for cardiovascular disease, cerebrovascular disease or renal disease, such as any of the following (NOT an exhaustive list):**

- Hypertension
- Dyslipidemia / Hyperlipidemia
- Diabetes Mellitus
- Congestive Heart Failure (NYHA I)
- Coronary Artery Disease (Atherosclerosis)
- Peripheral Arterial Disease
- Smoking
- Creatinine Clearance < 60 mL/min or 1 mL/sec

Use of NSAIDs, such as TARO-DICLOFENAC, can lead to new hypertension or can worsen pre-existing hypertension, either of which may increase the risk of cardiovascular events as described above. Thus blood pressure should be monitored regularly. Consideration should be



given to discontinuing TARO-DICLOFENAC should hypertension either develop or worsen with its use.

Use of NSAIDs, such as TARO-DICLOFENAC, can induce fluid retention and edema, and may exacerbate congestive heart failure, through a renally-mediated mechanism.

For patients with a high risk of developing an adverse CV event, other management strategies that do NOT include the use of NSAIDs should be considered first. **To minimize the potential risk for an adverse CV event, the lowest effective dose should be used for the shortest possible duration.**

### **Driving and Operating Machinery**

Some patients may experience drowsiness, dizziness, vertigo, insomnia or depression with the use of TARO-DICLOFENAC. If patients experience these side effects, they should exercise caution in carrying out activities that require alertness.

### **Gastrointestinal**

In clinical studies, diclofenac sodium solution has not been associated with serious gastrointestinal (GI) toxicity, such as peptic ulceration, perforation and GI bleeding commonly associated with NSAIDs.

Serious GI toxicity, such as peptic ulceration, perforation and gastrointestinal bleeding, sometimes severe and occasionally fatal, can occur at any time, with or without symptoms, in patients treated with NSAIDs, including diclofenac sodium.

Gastrointestinal symptoms, such as dyspepsia, are common, usually developing early in therapy. Healthcare professionals should remain alert for the signs and symptoms of ulceration and bleeding in patients treated with NSAIDs, even in the absence of previous GI tract symptoms.

In patients observed in clinical trials of NSAIDs given orally, symptomatic upper GI ulcers, gross bleeding, or perforation appear to occur in approximately 1% of patients treated for 3 -6 months and in about 2-4% of patients treated for one year. The incidence of these complications is related to dose, past history of known ulcer disease, and advanced age.

TARO-DICLOFENAC should be given under close medical supervision to patients with a history of ulcer of the gastrointestinal tract, or inflammatory disease of the gastrointestinal tract, such as ulcerative colitis or Crohn's disease. In these cases the healthcare professionals must weigh the benefits of treatment against the possible hazards.

Patients should be informed about the signs and/or symptoms of serious GI toxicity and instructed to contact a healthcare professional immediately if they experience persistent dyspepsia or other symptoms or signs suggestive of gastrointestinal ulceration or bleeding.

Because serious GI tract ulceration and bleeding can occur without warning symptoms, healthcare professionals should follow patients for signs and symptoms of ulceration and bleeding and should inform the patients of the importance of this follow-up.

If ulceration is suspected or confirmed, or if GI bleeding occurs, TARO-DICLOFENAC should be discontinued immediately, appropriate treatment instituted and the patient monitored closely.

No studies, to date, have identified any group of patients not at risk of developing ulceration and bleeding. The major risk factors are a prior history of serious GI events and increasing age. Possible risk factors include *Helicobacter pylori* infection, excess alcohol intake, smoking, concomitant oral steroids, anticoagulants, anti-platelet agents (including ASA) and selective serotonin reuptake inhibitors (SSRIs).

There is no definitive evidence that the concomitant administration of histamine H<sub>2</sub>-receptor antagonists and/or antacids will either prevent the occurrence of gastrointestinal side effects or allow the continuation of TARO-DICLOFENAC therapy when, and if, these adverse reactions appear.

### **Genitourinary**

Some NSAIDs are known to cause persistent urinary symptoms (bladder pain, dysuria, urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with an NSAID. Some cases have become severe on continued treatment. Should urinary symptoms occur, treatment with TARO-DICLOFENAC must be stopped immediately to obtain recovery. This should be done before any urological investigation or treatment is carried out.

### **Hematologic**

In clinical studies with diclofenac sodium solution, abnormal hemoglobin, white blood cell (WBC) or platelet counts have not been observed.

The effect of diclofenac sodium solution on platelet function was studied in 10 healthy patients randomly selected to participate in a sub-study of multiple-dose pharmacokinetic study where 40 drops of diclofenac sodium solution were applied to each knee four times a day for 7 days. Following 7-day treatment with diclofenac sodium solution, the mean change in % aggregation for ADP-collagen-, epinephrine- and arachidonic acid-induced aggregation was 1.31%, -0.19%, 9.85% and -0.95%, respectively. These results indicate that there was no marked effect on platelet aggregation after application of the maximum clinical dose for 7 days.

Diclofenac sodium increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII. Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers. The mean changes were observed to be less than 1 second in both instances, and are unlikely to be clinically important.

Drugs inhibiting prostaglandin biosynthesis interfere with platelet function to varying degrees; therefore, patients who may be adversely affected by such an action, such as those on anti-coagulants or suffering from haemophilia or platelet disorders, should be carefully observed when TARO-DICLOFENAC is administered.

Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anemia and agranulocytosis) associated with the use of NSAIDs are rare, but could occur with severe consequences. Patients on long-term diclofenac sodium treatment should have their hematopoietic system evaluated periodically.

## **Hepatic/Biliary/Pancreatic**

As with other NSAIDs, including TARO-DICLOFENAC, borderline elevations of one or more liver enzyme tests (AST, ALT, alkaline phosphatase) may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. Toxicity studies in animals with high doses of DMSO have shown occasional, transient elevation of liver function tests.

In two clinical trials with diclofenac sodium solution, a mild elevation of AST was seen in 4 of 117 (3.4%) patients using diclofenac sodium solution, 2 of 109 (1.8%) using vehicle-control (both of these solutions contained DMSO 45.5%) and 1 of 110 (0.9%) using Placebo. A mild elevation of ALT was seen in 4 of 117 (3.4%) patients using diclofenac sodium solution, 6 of 111 (5.4%) using vehicle-control and 2 of 108 (1.9%) using placebo. In most cases the increase was minimal and in two patients (one treated with diclofenac sodium solution, one treated with vehicle-control) the increase was 2.5 times normal.

In post-marketing reports of patients receiving diclofenac, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with TARO-DICLOFENAC. Post-marketing surveillance has reported cases of severe hepatic reactions including jaundice, fulminant hepatitis with and without jaundice, liver necrosis and hepatic failure. Some of these cases have resulted in fatalities or liver transplantation.

Transaminases should be measured periodically in patients receiving TARO-DICLOFENAC because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. Severe hepatic reactions can occur at any time during treatment with diclofenac. Although such reactions are rare, if abnormal liver function tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop (e.g. jaundice), or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), this drug should be discontinued immediately.

To minimize the possibility that hepatic injury will become severe between transaminase measurements, patients should be informed of warning signs and symptoms of hepatotoxicity (e.g. nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms), and the appropriate action they should take if these signs and symptoms appear. Use of diclofenac is contraindicated in patients with significant hepatic impairment or active liver disease. If there is a need to prescribe this drug to patients with liver impairment, it must be done under strict observation.

Caution is advised when using diclofenac sodium in patients with hepatic porphyria, since diclofenac sodium may trigger an attack.

## **Immune**

In common with other NSAIDs, diclofenac sodium may mask the usual signs of infection (*i.e.* fever).

## *Aseptic Meningitis*

In rare cases, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissue diseases, etc.) seem to be pre-disposed. Therefore, in such patients, the healthcare professional must be vigilant to the development of this complication.

### **Monitoring and Laboratory Tests**

The following testing or monitoring should be considered (note: this is not an exhaustive list):

**Cardiovascular:** Blood pressure monitoring should be considered. See [2 CONTRAINDICATIONS](#), [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#), [7 WARNINGS AND PRECAUTIONS](#), Cardiovascular.

**Hematology:** Concurrent therapy with anticoagulants may require monitoring of the international normalized ratio (INR). Hemoglobin, hematocrit, red blood cells (RBCs), white blood cells (WBCs), and platelets may require monitoring. See [7 WARNINGS AND PRECAUTIONS](#), Hematologic and [9 DRUG INTERACTIONS](#).

Lithium plasma concentration (in case of lithium co-prescription) should be monitored. See [9 DRUG INTERACTIONS](#).

**Hepatic:** Serum transaminase and bilirubin may require monitoring. See [7 WARNINGS AND PRECAUTIONS](#), Hepatic/Biliary/Pancreatic.

**Ophthalmologic:** If ophthalmological symptoms develop, TARO-DICLOFENAC should be discontinued and an ophthalmologic examination performed. See [7 WARNINGS AND PRECAUTIONS](#), Ophthalmologic.

**Renal:** Serum creatinine, creatinine clearance, serum urea and electrolytes including serum potassium may require monitoring. See [2 CONTRAINDICATIONS](#), [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#), [4.2 Recommended Dose and Dosage Adjustment](#), [7 WARNINGS AND PRECAUTIONS](#), Renal and [9 DRUG INTERACTIONS](#).

**Pregnancy:** TARO-DICLOFENAC is contraindicated for use in pregnancy. See [2 CONTRAINDICATIONS](#).

### **Ophthalmologic**

Blurred and/or diminished vision has been reported with the use of NSAIDs. Changes in the refractive index and lens opacities have been seen in non-primate animals with chronic administration of dimethyl sulfoxide, in doses far in excess of those used in humans. If ophthalmological symptoms develop, TARO-DICLOFENAC should be discontinued and an ophthalmologic examination performed.

### **Peri-operative Considerations**

See [2 CONTRAINDICATIONS](#).

### **Renal**

In clinical studies with diclofenac sodium solution, increase in urea or creatinine, or any other renal toxicity has not been observed.

Long-term administration of NSAIDs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic syndrome.

A second form of renal toxicity has been seen in patients with pre-renal conditions leading to reduction in renal blood flow or blood volume, where the renal prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose- dependent reduction in prostaglandin formation and may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

Diclofenac sodium and its metabolites are eliminated primarily (60%) by the kidneys; therefore, TARO-DICLOFENAC should be used with great caution in patients with impaired renal function. In these cases, utilization of lower doses of TARO-DICLOFENAC should be considered and patients carefully monitored.

#### *Fluid and Electrolyte Balance*

In clinical studies with diclofenac sodium solution, fluid or electrolyte abnormalities have not been observed.

Fluid retention and edema have been observed in patients treated with diclofenac sodium. Therefore, as with many other NSAIDs, the possibility of precipitating congestive heart failure in elderly patients or those with compromised cardiac function should be borne in mind. TARO-DICLOFENAC should be used with caution in patients with heart failure, hypertension or other conditions predisposing to fluid retention.

With NSAID treatment, there is a potential risk of hyperkalemia, particularly in patients with conditions such as diabetes mellitus or renal failure; elderly patients; or in patients receiving concomitant therapy with  $\beta$ -adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists or some diuretics. Patients at risk should be monitored periodically.

#### **Sensitivity/Resistance**

Dimethyl sulfoxide may initiate the liberation of histamine and occasional hypersensitivity reactions have occurred with topical administration. If anaphylactoid symptoms develop, appropriate therapy should be instituted and further use of TARO-DICLOFENAC immediately discontinued.

As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can occur without prior exposure to the drug. Careful questioning for patient history of asthma, nasal polyps, urticaria, and hypotension associated with NSAIDs is important before starting therapy. Because hypersensitivity reactions may occur even at a low systemic level, the possibility of such adverse effects with TARO-DICLOFENAC cannot be completely excluded.

These reactions are potentially life-threatening, but may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients should be advised that if they experience a generalized skin rash they should discontinue TARO-DICLOFENAC and contact their healthcare professional for assessment and advice, including which additional therapies to discontinue

## Skin

TARO-DICLOFENAC should not be applied to open, abraded or infected skin, and it should not be used under occlusive dressings. Contact with the eyes or mucous membranes should be avoided.

Patients should be warned against excessive exposure to sunlight in order to reduce the incidence of photosensitivity.

### *Serious skin reactions*

Use of some NSAIDs, such as TARO-DICLOFENAC, have been associated with rare post-market cases of serious, fatal or otherwise life-threatening skin reactions, including:

- drug reaction with eosinophilia and systemic symptoms (DRESS)
- Stevens-Johnson syndrome (SJS)
- toxic epidermal necrolysis (TEN)
- exfoliative dermatitis
- erythema multiforme

Patients appear to be at higher risk for these events early in the course of therapy, with the onset of cases usually occurring within the first month of treatment. These reactions may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients should be advised that they should discontinue their NSAID at the first appearance of a skin rash, mucosal lesions or any other sign of hypersensitivity, and contact their physician immediately for assessment and advice, including which therapies to discontinue.

DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection, and eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.

## 7.1 Special Populations

### 7.1.1 Pregnant Women

TARO-DICLOFENAC is contraindicated for use during pregnancy because of risks of premature closure of the ductus arteriosus and the potential to prolong parturition (see [2 CONTRAINDICATIONS](#) and [16 NON-CLINICAL TOXICOLOGY](#)).

Published studies and post-marketing reports describe maternal NSAID use at approximately 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment or failure. NSAIDs were shown to cause significant reduction in fetal urine production prior to reduction of amniotic fluid volume. There have also been a limited number of case reports of maternal NSAID use

and neonatal renal dysfunction and renal impairment without oligohydramnios, some of which were irreversible, even after treatment discontinuation.

These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Complications of prolonged oligohydramnios may for example, include limb contractures and delayed lung maturation. In some post-marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo-fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.

In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis period.

### 7.1.2 Breast-feeding

TARO-DICLOFENAC is contraindicated in breast-feeding women (see [2 CONTRAINDICATIONS](#)).

### 7.1.3 Pediatrics

**Pediatrics (<18 years of age):** No data are available to Health Canada, therefore TARO-DICLOFENAC is contraindicated in the pediatric population (see [2 CONTRAINDICATIONS](#)).

### 7.1.4 Geriatrics

**Geriatrics (≥ 65 years of age):** Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety (see [4.2 Recommended Dose and Dosage Adjustment](#)).

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

Adverse reaction reporting is based on double-blind, controlled clinical studies in which 446 patients were exposed to diclofenac sodium solution. Mean drop-out rates were: diclofenac sodium solution, 22.0%; vehicle-control (C), 28.3%; diclofenac control, 19.2%; placebo, 20.6%.

Application-site, dermatological reactions are the most commonly seen adverse events with diclofenac sodium solution (see [Table 3](#)).

The most common adverse reactions encountered with oral NSAIDs are gastrointestinal, of which peptic ulcer, with or without bleeding, is the most severe. Fatalities have occurred, particularly in the elderly. The most severe, albeit rare, dermatological reactions observed were erythema multiforme (Stevens-Johnson syndrome and Lyell's syndrome).

## 8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

The following table lists all adverse events, regardless of causality, occurring in > 2% of patients receiving diclofenac sodium solution from five controlled studies conducted in patients with osteoarthritis that included a vehicle-control, active-control and/or placebo-control group.

**Table 3 – Adverse Events Occurring in >2% of Diclofenac Sodium Solution Patients in Five Vehicle-Controlled Studies**

| Adverse Event                                | Diclofenac Sodium Solution (n=446) (%) | Control-DMSO <sup>1</sup> (n=442) (%) | Control-Diclofenac <sup>2</sup> (n=52) (%) | Placebo <sup>3</sup> (n=175) (%) |
|--|--|---------------------------------------|--|----------------------------------|
| <b>Gastrointestinal</b>                      |  |                                       |  |                                  |
| Dyspepsia                                    | 4.48                                   | 3.85                                  | 9.62                                       | 4                                |
| Nausea                                       | 2.02                                   | 2.26                                  | 3.85                                       | 1.71                             |
| <b>Central and Peripheral Nervous System</b> |  |                                       |  |                                  |
| Paresthesia                                  | 2.02                                   | 1.58                                  | 0  | 1.14                             |
| Paresthesia (Application Site)               | 7.85                                   | 9.05                                  | 7.69                                       | 10.29                            |
| <b>Skin and Appendages</b>                   |  |                                       |  |                                  |
| Application-Site Reaction                    | 2.47                                   | 1.13                                  | 5.77                                       | 1.71                             |
| Dry Skin (Application Site)                  | 41.93                                  | 23.3                                  | 23.08                                      | 6.86                             |
| Pruritus (Application Site)                  | 2.91                                   | 4.52                                  | 3.85                                       | 4                                |
| Rash   | 2.02                                   | 1.81                                  | 3.85                                       | 2.86                             |
| Rash (Application Site)                      | 9.64                                   | 4.98                                  | 7.69                                       | 2.86                             |
| <b>Special Senses</b>                        |  |                                       |  |                                  |
| Taste Perversion                             | 3.81                                   | 3.62                                  | 0  | 4.57                             |
| <b>Respiratory</b>                           |  |                                       |  |                                  |
| Pharyngitis                                  | 5.38                                   | 2.71                                  | 5.77                                       | 6.86                             |
| <b>Musculoskeletal</b>                       |  |                                       |  |                                  |
| Arthralgia                                   | 16.82                                  | 16.52                                 | 40.38                                      | 37.14                            |
| Arthrosis                                    | 4.04                                   | 3.85                                  | 3.85                                       | 12                               |
| Joint Disorder                               | 4.71                                   | 5.43                                  | 7.69                                       | 15.43                            |
| <b>Body As A Whole</b>                       |  |                                       |  |                                  |
| Abdominal Pain                               | 3.14                                   | 1.58                                  | 0  | 5.14                             |
| Back Pain                                    | 6.5                                    | 5.66                                  | 15.38                                      | 7.43                             |
| Flu Syndrome                                 | 4.04                                   | 4.07                                  | 0  | 4.57                             |
| Headache                                     | 12.11                                  | 13.12                                 | 32.69                                      | 26.86                            |
| Infection                                    | 3.14                                   | 2.71                                  | 11.54                                      | 4.57                             |
| Pain   | 6.05                                   | 6.33                                  | 17.31                                      | 10.86                            |

<sup>1</sup> Contains the full carrier with DMSO, no diclofenac sodium

<sup>2</sup> Contains negligible DMSO with the full dose of diclofenac sodium

<sup>3</sup> Contains negligible DMSO with no diclofenac sodium



### 8.3 Less Common Clinical Trial Adverse Reactions

The following spontaneous adverse events occurred in 0.2 to 1.8% of patients treated with diclofenac sodium solution regardless of causality:

**Gastrointestinal:** colitis, constipation, diarrhea, dry mouth, flatulence, gastritis, gastroenteritis, gingivitis, periodontal abscess, rectal disorder, thirst, tooth caries, vomiting;

**Central and Peripheral Nervous System:** aphasia, confusion, dizziness, depression, dysthymia, hypertonia, insomnia, migraine, nervousness, neuritis, sleep disorder, speech disorder, thinking abnormal, vertigo;

**Skin and Appendages:** acne, acne (application site), contact dermatitis, dry skin, furunculosis, hair disorder, maculopapular rash, nail disorder, pruritus, pustular rash, skin nodule, urticaria, vesiculobullous rash;

**Cardiovascular:** arrhythmia, arteriosclerosis, bradycardia, cardiovascular disorder, hypertension, myocardial infarction, palpitation, vasodilation, vasodilation (application site);

**Special Senses:** amblyopia, cataract, ear pain, eye pain, lacrimation disorder;

**Hemic and Lymphatic:** ecchymosis;

**Urogenital:** dysmenorrhea, prostatic specific antigen increase, testis disorder, vaginal hemorrhage;

**Metabolic and Nutritional:** edema, gout, hypercholesterolemia, peripheral edema;

**Respiratory:** asthma, bronchitis, congestion, cough increased, dyspnea, epistaxis, rhinitis, sinusitis;

**Musculoskeletal:** abnormal gait, arthritis, bone pain, leg cramps, myasthenia;

**Body as a Whole:** accidental injury, allergic reaction, asthenia, body odour, carcinoma, chest pain, chills, face edema, fever, halitosis, hernia, malaise, neck pain, neck rigidity.

In a controlled clinical trial conducted to assess the alternative dose regimen of 50 drops t.i.d, a total of 311 patients received at least one dose of diclofenac sodium solution for mean treatment duration of 66 days. The safety profile observed in this study was consistent with that reported in previous studies, the primary adverse events experienced by diclofenac sodium solution patients being application-site reactions.

In a long-term, uncontrolled clinical trial (approximately 800 patients were treated with diclofenac sodium solution for one year or longer), the adverse event profile was similar to that observed in the controlled clinical trials.

### 8.5 Post-Market Adverse Reactions

In post-marketing surveillance for diclofenac sodium solution and other diclofenac containing products, the following adverse reactions have been reported:

**Body as a whole:** Abdominal pain, Accidental injury, Allergic reaction, Asthenia, Back pain, Body odor, Chest pain, Edema, Face edema, Halitosis, Headache, lack of drug effect, Neck rigidity, Pain;

**Cardiovascular:** Cardiovascular disorder, Palpitation;

**Digestive:** Diarrhea, Dry mouth, Dyspepsia, Mouth ulceration, Nausea, Rectal hemorrhage, Ulcerative stomatitis;

**Hepatic:** Hepatotoxicity, severe hepatic reactions including liver necrosis, jaundice, fulminant hepatitis with and without jaundice and liver failure, with a fatal outcome or requiring liver transplantation (see [7 WARNINGS AND PRECAUTIONS](#), Hepatic/Biliary/Pancreatic);

**Metabolic and nutritional:** Creatinine increased;

**Musculoskeletal:** Leg cramps, Myalgia;

**Nervous:** Depression, Dizziness, Drowsiness, Paresthesia, Paresthesia, app. site;

**Respiratory:** Asthma, Dyspnea, Laryngismus, Laryngitis, Pharyngitis;

**Skin and appendages:** At the Application site: Contact dermatitis, Contact dermatitis with vesicles, Dry skin, Pruritus, Rash. Other skin adverse reaction: Rash, Skin discoloration, Urticaria;

**Special senses:** Abnormal vision, Blurred vision, Cataract, Ear pain, Eye disorder, Eye pain, Taste perversion.

## 9 DRUG INTERACTIONS

### 9.2 Drug Interactions Overview

Diclofenac metabolism is predominantly mediated via cytochrome P450 CYP 2C9 in the liver. Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates should be administered diclofenac with caution as they may have abnormally high plasma levels due to reduced metabolic clearance. Caution is recommended when co-prescribing diclofenac with potent CYP2C9 inhibitors (such as sulfapyrazole and voriconazole), which could result in a significant increase in peak plasma concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.

### 9.3 Drug-Behavioural Interaction

**Alcohol:** There may be an increased risk of GI side effects, including ulceration or hemorrhage, when taken concomitantly with NSAIDs.

### 9.4 Drug-Drug Interactions

The drugs listed below are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

**Acetylsalicylic Acid (ASA) or other NSAIDs:** The use of TARO-DICLOFENAC in addition to any other NSAID, including those over-the-counter ones (such as ASA and ibuprofen) is not recommended due to the possibility of additive side effects. Low dose ASA (<325 mg/day) for cardiovascular prophylaxis, is permitted.

**Digoxin:** Diclofenac sodium may increase the plasma concentration of digoxin. Dosage adjustment of digoxin may be required.

**Anticoagulants, Heparin, Thrombolytic Agents and Other Platelet Aggregation Inhibitors:** Numerous studies have shown that the concomitant use of NSAIDs and anticoagulants increases the risk of GI adverse events such as ulceration and bleeding.

Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function, concurrent therapy of TARO-DICLOFENAC with warfarin requires close monitoring to be certain that no change in anticoagulant dosage is necessary.

**Oral Hypoglycemics:** Pharmacodynamic studies have shown no potentiation of effect with concurrent administration with diclofenac sodium; however, there are isolated reports of both hypoglycemic and hyperglycemic effects in the presence of diclofenac sodium, which necessitated changes in the dosage of hypoglycemic agents.

**Diuretics:** NSAIDs have been reported to decrease the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium, thus making it necessary to monitor levels.

**Antihypertensives:** Like other NSAIDs, diclofenac sodium can reduce the antihypertensive effects of propranolol and other beta-blockers, as well as other antihypertensive agents.

**Glucocorticoids:** Numerous studies have shown that concomitant use of NSAIDs and oral glucocorticoids increases the risk of GI side effects such as ulceration and bleeding. This is especially the case in older individuals (>65 years of age).

**Methotrexate:** Caution should be exercised when NSAIDs are administered less than 24 hours before or after treatment with methotrexate. Elevated blood concentrations of methotrexate may occur, increasing its toxicity.

**Acetaminophen:** There may be an increased risk of adverse renal effects when administered concomitantly with NSAIDs.

**Cyclosporine:** The nephrotoxicity of cyclosporine may be increased because of the effects of NSAIDs on renal prostaglandins.

**Lithium:** Lithium plasma concentrations will increase when administered concomitantly with diclofenac sodium (which affects lithium renal clearance). Dosage adjustment of lithium may be required.

**Probenecid:** May decrease the excretion and increase serum concentration of NSAIDs, possibly enhancing effectiveness and/or increasing the potential for toxicity. Concurrent therapy of NSAIDs with probenecid requires close monitoring of dosage.

**Quinolone Antibacterials:** There have been isolated reports of convulsions, which may have been due to concomitant use of quinolones and NSAIDs.

**Phenytoin:** When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.

**Sulfinpyrazone:** Concomitant administration of diclofenac and sulfinpyrazone could result in a significant increase in peak plasma concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.

**Voriconazole:** Concomitant administration of diclofenac and voriconazole could result in a significant increase in peak plasma concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.

## 9.5 Drug-Food Interactions

Interactions with food have not been established.

## 9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

## 9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

# 10 CLINICAL PHARMACOLOGY

## 10.1 Mechanism of Action

Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) of the arylacanoic acid group, with analgesic and anti-inflammatory properties. The mode of action of diclofenac sodium is not fully known, but it is considered to be primarily through its inhibitory effects on prostaglandin synthesis by interfering with the action of prostaglandin synthetase/cyclo-oxygenase, isoforms 1 and 2 (COX-1 and COX-2). It does not act through the pituitary-adrenal axis.

## 10.2 Pharmacodynamics

Diclofenac sodium is an NSAID with analgesic and antipyretic properties. Diclofenac inhibits prostaglandin synthesis by interfering with the action of prostaglandin synthetase/ COX-1 and COX-2. This inhibitory effect may partially explain its actions. Diclofenac sodium demonstrated excellent analgesic potential when compared to other NSAIDs. The analgesic potential of the most active metabolite of diclofenac sodium was about 50 times less than the potential of the diclofenac sodium itself.

Although diclofenac sodium does not alter the course of the underlying disease, it has been found to relieve pain, reduce fever, swelling and tenderness, and increase mobility in patients with various rheumatic disorders.

## 10.3 Pharmacokinetics

### Absorption

**Oral administration:** Orally administered diclofenac sodium is rapidly and almost completely absorbed and distributed through the blood to all organs. The plasma concentration shows a linear relationship to the administered dose. After administration of 50 mg of enteric-coated diclofenac sodium, on an empty stomach, the mean peak plasma concentration ( $C_{MAX}$ ) was reported as approximately 1,500 ng/mL after about 2 hours. No accumulation occurs, provided the recommended dosage intervals are observed.

Following a single topical application of diclofenac sodium solution (1.0 mL) to a single knee, the mean peak plasma diclofenac sodium concentration ( $C_{MAX}$ ) in six volunteers was  $9.7 \pm 4.7$  ng/mL after 24 to 48 h ( $T_{MAX}$ ). The mean total urinary recovery of diclofenac sodium was 3.68%.

Following multiple doses of diclofenac sodium solution, 40 drops (one knee) or 80 drops (two knees, four times a day for 84 days, to 20 patients, the mean plasma diclofenac sodium level was  $8.95 \pm 9.17$  ng/mL.

Two additional PK studies had been performed. In an open-label, single-dose pharmacokinetic study, a total of 80 drops of diclofenac sodium solution were applied on both knees (40 drops per knee). After a single administration of diclofenac sodium solution a maximum diclofenac concentration in plasma of 8.05 ng/mL was reached in about 10 h, and diclofenac remained measurable up to 72 h post-dose in 18 subjects. Mean elimination half-life was 37h (13 subjects).

In an open-label, multiple dose pharmacokinetic study, a total of 80 drops of diclofenac sodium solution (40 drops per knee), were applied on both knees over 7 days with the final dose on the morning of Day 8. Additionally, pre-dose samples were collected on Days 6, 7 and 8. Diclofenac reached plasma concentration levels at or near steady state on Day 6. After the last dose of diclofenac sodium solution on Day 8, mean plasma C<sub>max</sub> value of diclofenac was 19.4 ng/mL and mean T<sub>max</sub> was 4.0 hrs. The apparent terminal half-life (t<sub>1/2</sub>) was 79.0 h.

### **Distribution**

Diclofenac sodium is extensively bound (99%) to serum albumin. The apparent volume of distribution is 0.12 to 0.17 L/kg.

### **Metabolism**

Diclofenac sodium, regardless of the route of application, once systemically absorbed, undergoes single and multiple hydroxylation followed by o-methylation of the hydroxy metabolites, producing 3'-, 4'-, 5- hydroxy, 4'-5-hydroxy and 3'-hydroxy-4'-methoxy derivatives of diclofenac sodium. These phenolic metabolites are largely inactive and, along with the parent compound, are converted mostly to glucuronide conjugates.

### **Elimination**

**Oral administration:** Following oral administration, plasma clearance of diclofenac sodium is reported as  $263 \pm 56$  mL/minute. The mean terminal drug half-life in plasma is 1.8 hours. About 60% of the drug and its metabolites are eliminated in the urine and the balance through biliary secretion into the feces. More than 90% of an oral dose is accounted for in elimination products, within 72 hours. About 1% of an oral dose is excreted unchanged in urine.

After topical administration, of diclofenac sodium solution the mean total urinary recovery of diclofenac sodium after 120 h was 3.68%. The peak urinary excretion rate was reached by 24 h and was maintained until 48-72 h.

### **Dimethyl sulfoxide (DMSO) pharmacokinetics in humans**

Following topical application, DMSO is absorbed and generally distributed throughout the body tissues and fluids. DMSO is detectable in serum after 5 minutes. The peak serum concentration occurs in 4 – 6 h. DMSO is metabolized by oxidation to dimethyl sulfone or by reduction to

dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces. Dimethyl sulfide is a volatile gas that is eliminated through the breath and skin and is responsible for the garlic-like odour sometimes noticed by patients. Trace amounts persist in serum for more than 2 weeks after a single intra vesical instillation. No residual accumulation of DMSO has occurred in patients who have received treatment for protracted periods of time. Following multiple doses of diclofenac sodium solution, 40 drops (one knee) or 80 drops (two knees) *q.i.d.* for up to 84 days, the mean plasma diclofenac sodium level was  $8.95 \pm 9.17$  ng/mL. The mean whole blood level of (DMSO) was  $647.8 \pm 659.3$  ng/mL, in 18 patients, up to 6 hours following the last application.

Two additional Pharmacokinetic studies have been performed. In an open-label, single-dose pharmacokinetic study, a total of 80 drops of diclofenac sodium solution were applied on both knees (40 drops per knee). After a single administration of diclofenac sodium solution, maximum DMSO concentration in plasma of  $0.48 \mu\text{g/mL}$  was reached in about 8 hours, and DMSO remained measurable up to 24 h post-dose in 18 subjects. Mean elimination half-life was 8.4h (9 subjects).

In an open-label, multiple dose pharmacokinetic study, a total of 80 drops of diclofenac sodium solution (40 drops per knee), were applied on both knees over 7 days with the final dose on the morning of Day 8. DMSO reached plasma concentration levels at or near steady state on Day 6. Following the last dose of diclofenac sodium solution on Day 8, mean  $C_{\text{max}}$  value of DMSO was  $1.2 \mu\text{g/mL}$  and mean  $T_{\text{max}}$  value was 3.8 h. The mean apparent terminal half-life ( $t_{1/2}$ ) was 43 hrs. Dimethyl sulfone (DMSO<sub>2</sub>) reached plasma concentration levels at or near steady state on Day 6. Following the last dose of diclofenac sodium solution on Day 8,  $C_{\text{max}}$  values of DMSO<sub>2</sub> were  $18.0 \mu\text{g/mL}$  and mean  $T_{\text{max}}$  value was 9.4 h.

## **11 STORAGE, STABILITY AND DISPOSAL**

Store at room temperature (15-25°C). Store upright. Keep out of the reach of children. Any unused product or waste material should be disposed of in accordance with local requirements.

## **12 SPECIAL HANDLING INSTRUCTIONS**

Not applicable

## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: Diclofenac sodium, U.S.P.

Chemical name: 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid monosodium salt

Molecular formula and molecular mass: C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub>, 318.13 g/mol

Structural formula:



Physicochemical properties: White to off-white powder with a salty, bitter taste.  
Diclofenac sodium is 2% soluble in water (pH 7.7, 25°C),  
practically insoluble in aqueous acidic solutions and  
sparingly soluble in water at pH 5.2.

## 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

#### Osteoarthritis of the knee

**Table 4 – Summary of clinical trials in patients with osteoarthritis of the knee**

| Study # | Study design   | Duration           |
|---------|--|--------------------|
| Study 1 | Double-blind, vehicle-controlled clinical trial in patients with osteoarthritis of the knee              | 84 days (12 weeks) |
| Study 2 | Double-blind, vehicle-controlled clinical trial in patients with osteoarthritis of the knee              | 42 days (6 weeks)  |
| Study 3 | Double-blind, vehicle- and placebo-controlled clinical trial in patients with osteoarthritis of the knee | 28 days (4 weeks)  |
| Study 4 | Randomized, double blind, double-dummy clinical trial in patients with osteoarthritis of the knee        | 84 days (12 weeks) |

#### **Study 1: Efficacy Data for 84-day Vehicle-Controlled Study**

In an 84-day (12-week), double-blind, vehicle-controlled clinical trial in patients with osteoarthritis of the knee, the efficacy of diclofenac sodium solution was demonstrated by three primary variables-pain and physical function, as measured with the WOMAC LK3.1 Osteoarthritis Index-plus Patient Global Assessment. Efficacy was confirmed by the secondary variable, stiffness, as measured by WOMAC LK3.1 Osteoarthritis Index.

For all treated patients (ALL), descriptive statistical analysis revealed that the diclofenac sodium solution group showed greater improvement in scores than the vehicle-control group for all variables. Based on ANCOVA, using baseline score as a covariate, diclofenac sodium solution was found to be statistically significantly ( $p < 0.05$ ) more effective than vehicle-control for all variables (see [Table 5](#)).

#### **Study 2: Efficacy Data for 42-day Vehicle-Controlled Study**

In a 42-day (6-week), double-blind, vehicle-controlled clinical trial in patients with osteoarthritis of the knee, the efficacy of diclofenac sodium solution was demonstrated by three primary variables-pain and physical function, as measured with the WOMAC LK3.1 Osteoarthritis Index-plus Patient Global Assessment. Efficacy was confirmed by the secondary variable, stiffness, as measured by WOMAC LK3.1 Osteoarthritis Index.

For all treated patients (ALL), descriptive statistical analysis revealed that the diclofenac sodium solution group showed greater improvement in scores than the vehicle-control group for all variables. Based on ANCOVA, using baseline score as a covariate, diclofenac sodium solution was found to be statistically significantly ( $p < 0.05$ ) more effective than the vehicle-control for all variables (see [Table 6](#)).



### Study 3: Efficacy Data for 28-day Vehicle- and Placebo-Controlled Study

In a 28-day (4-week), double-blind, vehicle- and placebo-controlled clinical trial in patients with osteoarthritis of the knee, the efficacy of diclofenac sodium solution was demonstrated by the primary variable -pain, as measured with the WOMAC LK3.0 Osteoarthritis Index. Efficacy was confirmed by three secondary variables-physical function and stiffness, as measured by the WOMAC LK3.0 Osteoarthritis Index-plus Patient Global Assessment.

For all treated patients (ALL) descriptive statistical analysis revealed that the diclofenac sodium solution group showed greater improvement in scores than the vehicle-control and placebo groups for all WOMAC variables and for the Patient Global Assessment. Based on ANOVA (contrast analysis between least squares means) diclofenac sodium solution was found to be statistically significantly ( $p < 0.05$ ) more effective than vehicle- control and placebo for all variables (see [Table 7](#)).

Vehicle-control (C) and Placebo (P) were not statistically significantly different for any of the efficacy variables-pain ( $p = 0.557$ ); physical function ( $p = 0.412$ ); Patient Global Assessment ( $p = 0.882$ ); stiffness ( $p = 0.873$ ).

### Study 4: Efficacy data for 84-day study comparing diclofenac sodium solution (50 drops tid) and oral diclofenac (50 mg tid) (data normalized to 100 mm) VAS

The efficacy of diclofenac sodium solution (50 drops, 3 times a day) versus oral diclofenac (50 mg, 3 times a day) in relieving symptoms of primary osteoarthritis (OA) of the knee was assessed in an 84-day, randomized, double blind, double-dummy clinical study. The three primary efficacy variables were change from baseline to final assessment in (1) WOMAC Index VA3.1 pain subscale score, (2) WOMAC Index VA3.1 physical function subscale score and (3) Patient Global Assessment score. Efficacy was also supported by secondary efficacy variable, stiffness, as measured by WOMAC Index VA3.1.

The primary efficacy results on the Per Protocol (PP) dataset are summarized in [Table 8](#).

**Table 5 – Results of Study 1 in osteoarthritis of the knee**

| Improvement in Score of:         | ALL |                            |  |  |
|----------------------------------|-----|----------------------------|--|--|
|                                  | N   | Mean Baseline score (S.D.) | Mean Change in score <sup>1</sup> (S.D.) | p value <sup>2</sup><br>Diclofenac Sodium Solution > C |
| <b>Pain</b>                      |     |                            |  |  |
| Diclofenac Sodium Solution       | 164 | 13.0 (3.3)                 | -5.9 (4.7)                               | p = 0.0017   |
| Vehicle-control (C)              | 162 | 13.0 (3.4)                 | -4.4 (4.4)                               |  |
| <b>Physical Function</b>         |     |                            |  |  |
| Diclofenac Sodium Solution       | 164 | 42.0 (11.7)                | -15.3 (15.2)                             | p = 0.0024   |
| Vehicle-control (C)              | 162 | 41.3 (11.6)                | -10.3 (13.9)                             |  |
| <b>Patient Global Assessment</b> |     |                            |  |  |
| Diclofenac Sodium Solution       | 164 | 3.1 (0.7)                  | -1.3 (1.2)                               | p = 0.0052   |
| Vehicle-control (C)              | 162 | 3.1 (0.7)                  | -1.0 (1.1)                               |  |
| <b>Stiffness</b>                 |     |                            |  |  |
| Diclofenac Sodium Solution       | 164 | 5.2 (1.5)                  | -1.8 (2.1)                               | p = 0.0086   |
| Vehicle-control (C)              | 162 | 5.2 (1.5)                  | -1.3 (2.0)                               |  |

<sup>1</sup> Final - Baseline; WOMAC LK3.1

<sup>2</sup> ANCOVA (baseline score as a covariate)

**Table 6 – Results of Study 2 in osteoarthritis of the knee**

| Improvement in Score of:         | ALL |                            |  |   |
|----------------------------------|-----|----------------------------|--|---|
|                                  | N   | Mean Baseline score (S.D.) | Mean Change in score <sup>1</sup> (S.D.) | p value <sup>2</sup> Diclofenac Sodium Solution > C |
| <b>Pain</b>                      |     |                            |  |   |
| Diclofenac Sodium Solution       | 107 | 13.0 (3.2)                 | -5.3 (5.0)                               | p = 0.0040  |
| Vehicle-control (C)              | 109 | 12.8 (3.1)                 | -3.4 (4.3)                               |   |
| <b>Physical Function</b>         |     |                            |  |   |
| Diclofenac Sodium Solution       | 107 | 40.7 (12.0)                | -13.0 (16.2)                             | p = 0.0041  |
| Vehicle-control (C)              | 109 | 40.4 (11.2)                | -7.3 (13.4)                              |   |
| <b>Patient Global Assessment</b> |     |                            |  |   |
| Diclofenac Sodium Solution       | 107 | 3.1 (0.8)                  | -1.2 (1.3)                               | p = 0.0004  |
| Vehicle-control (C)              | 109 | 3.2 (0.8)                  | -0.7 (1.2)                               |   |
| <b>Stiffness</b>                 |     |                            |  |   |
| Diclofenac Sodium Solution       | 107 | 5.2 (1.5)                  | -1.7 (2.1)                               | p = 0.0023  |
| Vehicle-control (C)              | 109 | 5.2 (1.5)                  | -1.0 (1.9)                               |   |

<sup>1</sup>Final - Baseline; WOMAC LK3.1

<sup>2</sup>ANCOVA (baseline score as a covariate)

**Table 7 – Results of Study 3 in osteoarthritis of the knee**

| Improvement in Score of:   | ALL |                            |  |   |
|----------------------------|-----|----------------------------|--|---|
|                            | N   | Mean Baseline score (S.D.) | Mean Change in score <sup>2</sup> (S.D.) | p value <sup>1</sup>                      |
| <b>Pain</b>                |     |                            |  |   |
| Diclofenac Sodium Solution | 84  | 9.2 (0.4)                  | -3.9 (4.4)                               | Diclofenac Sodium Solution > C; p = 0.008 |
| Vehicle-control (C)        | 80  | 9.2 (0.4)                  | -2.3 (3.4)                               |   |
| Placebo (P)                | 84  | 9.6 (0.4)                  | -2.7 (4.0)                               | Diclofenac Sodium Solution > P; p = 0.034 |
| <b>Physical Function</b>   |     |                            |  |   |
| Diclofenac Sodium Solution | 84  | 29.5 (13.7)                | -11.5 (14.5)                             | Diclofenac Sodium Solution > C; p = 0.002 |
| Vehicle-control (C)        | 80  | 30.5 (11.8)                | -5.6 (11.1)                              |   |
| Placebo (P)                | 84  | 30.9 (13.1)                | -7.2 (12.3)                              | Diclofenac Sodium Solution > P; p = 0.017 |

| Improvement in Score of:                     | ALL |                            |  |   |
|--|-----|----------------------------|--|---|
|  | N   | Mean Baseline score (S.D.) | Mean Change in score <sup>2</sup> (S.D.) | p value <sup>1</sup>                      |
| <b>Patient Global Assessment<sup>3</sup></b> |     |                            |  |   |
| Diclofenac Sodium Solution                   | 82  | NA <sup>4</sup>            | 6.6 (3.1)                                | Diclofenac Sodium Solution > C; p = 0.040 |
| Vehicle-control (C)                          | 76  | NA <sup>4</sup>            | 7.7 (3.5)                                | Diclofenac Sodium Solution > P; p = 0.024 |
| Placebo (P)                                  | 83  | NA <sup>4</sup>            | 7.8 (3.0)                                |   |
| <b>Stiffness</b>                             |     |                            |  |   |
| Diclofenac Sodium Solution                   | 84  | 3.7 (1.7)                  | -1.5 (1.8)                               | Diclofenac Sodium Solution > C; p = 0.011 |
| Vehicle-control (C)                          | 80  | 3.5 (1.7)                  | -0.7 (2.0)                               | Diclofenac Sodium Solution > P; p = 0.006 |
| Placebo (P)                                  | 84  | 3.7 (1.8)                  | -0.7 (1.9)                               |   |

<sup>1</sup>ANOVA (contrast analysis between least squares means)

<sup>2</sup>Final - Baseline; WOMAC LK3.0

<sup>3</sup>Sum of weekly scores; some patients had no Patient Global Assessment data

<sup>4</sup>NA = Not applicable

**Table 8 – Results of Study 4 in osteoarthritis of the knee**

|   | WOMAC Pain        | WOMAC Physical    | Patient Global Assessment | Stiffness         |
|---|-------------------|-------------------|---------------------------|-------------------|
| <b>Diclofenac Sodium Solution:</b>            |                   |                   |                           |                   |
| N   | 237               | 237               | 234                       | 237               |
| Mean Change (SD)                              | -25.4 (24.0)      | -22.4 (23.3)      | -29.5 (30.9)              | -24.1 (29.5)      |
| <b>Oral Diclofenac:</b>                       |                   |                   |                           |                   |
| N   | 255               | 255               | 251                       | 255               |
| Mean Change (SD)                              | -28.0 (25.3)      | -26.6 (25.3)      | -33.8 (30.7)              | (-27.3 (30.5))    |
| <b>Absolute Differences of Means (95% CI)</b> | 2.7 (-1.7 to 7.0) | 4.2 (-0.1 to 8.5) | 4.3 (-1.2 to 9.8)         | 3.2 (-2.2 to 8.5) |

Randomized clinical trials with diclofenac sodium solution have NOT been designed to detect differences in cardiovascular adverse events in a chronic setting. However, large population-based observational studies, meta-analyses and systematic reviews suggest that diclofenac use is associated with an increased risk of cardiovascular thrombotic events, including myocardial infarction and ischemic stroke. Results of some studies suggest that the cardiovascular risk is

related to the dose and duration of diclofenac exposure and is greater in patients with risk factors for cardiovascular disease.

## 15 MICROBIOLOGY

No microbiological information is required for this drug product.

## 16 NON-CLINICAL TOXICOLOGY

### General Toxicology

#### Acute Toxicity

Diclofenac sodium:

| Species    | Route of Administration | LD <sub>50</sub> mg/kg |
|------------|-------------------------|------------------------|
| Mouse      | p.o.                    | 389                    |
|            | i.v.                    | 133                    |
| Rat        | p.o.                    | 173                    |
|            | i.v.                    | 106                    |
| Guinea-pig | p.o.                    | 1110                   |
|            | i.v.                    | 127                    |
| Rabbit     | p.o.                    | 194                    |

Symptoms included bradycardia and convulsions. The most frequent autopsy findings in animals that died were gastric irritation, perforation and their sequelae.

Dimethyl sulfoxide (DMSO):

The dermal LD<sub>50</sub> of DMSO is approximately 40,000 mg/kg in mice and rats. The oral and intravenous LD<sub>50</sub> values are >2,500 mg/kg in laboratory animals (mouse, rat, cat, dog and monkey).

There was no evidence of significant change in serum creatinine levels, and no histological change, with DMSO treatment. There was no additional nephrotoxicity in rats with dichromate- induced renal failure that were given DMSO compared to those that were given only the dichromate.

#### Long-Term Toxicity Studies

Diclofenac sodium:

Diclofenac sodium given orally to male and female rats, in doses of 0.25, 1.0 and 2.0 mg/kg/day, from 59 weeks (high-dose groups) to 98 weeks (low- and intermediate-dose groups) resulted in high, dose-related mortality caused by severe ulceration of the

gastrointestinal tract, with perforated ulcers leading to peritonitis and its sequelae. Hematological patterns showing neutrophilic leucocytosis and anemia were seen in the high- and intermediate-dose groups, particularly females at weeks 52 and 98. Females tended to develop enlarged adrenals and eventually experienced depressed glucose and elevated alkaline phosphatase levels. No increase in tumour incidence was observed in the drug-treated groups as compared to the control group.

Diclofenac sodium, given orally once daily to baboons (*Papio spp.*), at dose levels of 0, 5, 15 (reduced to 10 on day 254) and 50 (reduced to 30 on day 38) mg/kg/day, for up to 52 weeks, caused ulceration of the gastrointestinal tract, constipation and occasional diarrhea. In all groups receiving diclofenac, there was a dose-related fall in serum albumin level. In the recovery groups (controlled, low and intermediate), no intestinal lesions were present.

Dimethyl sulfoxide (DMSO):

Sixty percent (60%) or 100% DMSO was applied dermally to the shaved back of dogs and monkeys at doses of 3,300 to 33,000 mg/kg/week for 6 months. Initially, the skin became transiently reddened and warm, particularly with 100% DMSO. With continued application, erythema, desquamation and focal skin lesions occurred at three weeks and lasted for the duration of treatment. No other changes were observed.

DMSO administered in large doses to dogs, rabbits and pigs (particularly by the oral route) caused changes in the refractive index of the lens, with progressive myopia in the nucleus and an increase in hyperopia in the lens cortex. Chemical analysis indicated a reduction of the usual concentrations of soluble protein, urea, glutathione, uric and amino acid in the lens of affected eyes. The most sensitive animal was the rabbit, where the no observed effect level (NOEL) was 500 mg/kg/day. The lenticular changes seen in pigs after 27 weeks of topical DMSO at 2.7 – 4.5 g/kg doses were reversible. Two months after cessation of treatment, lens alterations regressed. However, following 5 g/day oral DMSO to dogs, lesions persisted after 8 months. No change to the lens of monkeys was detected at oral doses up to 5 g/kg/day for 100 days. The doses required to produce ocular changes in animals are far in excess of those that have been used clinically in humans.

Careful examination of patients who had received treatment with DMSO, 30 gm/day for 3 - 19 months revealed no adverse effects on the eye. In another study, 84 patients treated with DMSO, (average dose of 18.5 mL of 90% DMSO; average duration of 2.5 months) were examined ophthalmoscopically; no toxicity to the eye was observed. These exposures are orders of magnitude higher than the recommended dosage of diclofenac sodium solution.

Daily oral administration to rats of 50% DMSO, 5.0 g/kg for 45 days, caused slight weight loss. Microscopic examination of the liver showed necrosis of the liver cells (degenerative modifications of the hepatocytes) with inflammation and irritation of the portal spaces. However, orally administered doses of 2.0 g/kg affected neither weight gain nor growth of the 5 weeks old young animal. Histopathological examination showed no abnormality. In a study by Smith *et al.* (1967) of rats receiving daily oral DMSO doses of 1.0, 3.0 and 10 g/kg for 59 consecutive days, no grossly adverse effects were observed.

Smith *et al.* (1967) observed the response of three dogs to repeated oral doses of 2.5 – 10 g/kg DMSO, for 14 to 35 days. Halitosis, vomiting and ocular changes were observed. One dog that died had liver degeneration and hemorrhagic gastroenteropathy.

Rhesus monkeys, receiving 2 – 3 g/kg of DMSO intravenously, once daily for nine days, showed no evidence of damage to the liver, kidneys or eyes. Feinman and co-workers administered DMSO orally to monkeys for five consecutive days, at doses up to 4.0 g/kg, and reported no markedly adverse effects.

### **Carcinogenicity**

Carcinogenicity of DMSO in animals has not been determined.

### **Genotoxicity**

#### Diclofenac sodium solution

Diclofenac sodium solution was examined in three mutagenicity studies.

In the *Salmonella typhimurim* reverse mutation assay (Ames test), no mutagenic effect was observed for diclofenac sodium solution tested up to 5000 µg/plate in any of the test strains in the two experiments with or without metabolic activation.

Diclofenac sodium solution showed no clastogenic activity in human peripheral lymphocyte cultures at concentrations up to 5000 µg/mL, under either metabolic activation or non-activation conditions.

In the *in vivo* mouse micronucleus assay, diclofenac sodium solution -treated animals at the maximum tolerated dose of 12 mL/kg showed no significant increase in micronucleus frequency compared to negative control, whereas the known clastogenic agent cyclophosphamide induced large and statistically significant increases in micronucleus frequency.

#### Diclofenac sodium

Mutagenicity studies were carried out *in vitro* in bacteria and in mammalian cells, with and without microsomal activation. *In vivo* studies were also performed. Diclofenac sodium was not mutagenic in any of these test systems.

#### Dimethyl sulfoxide (DMSO)

DMSO was studied with the Ames test and was found to be non-mutagenic.

### **Reproductive and Developmental Toxicology**

#### Diclofenac sodium

Doses of 2 or 4 mg/kg/day were given orally to male and female rats with no noticeable effect on fertility. Dosing was carried out during pre-mating, mating, gestation and

lactation periods. At the higher dose, prolonged gestation and dystocia were observed. Embryo toxicity (low birth weight, failure to survive) was observed at both doses, but it was minimal at 2 mg/kg/day. Post-natal survival and growth of pups from drug-treated females were comparable to those of controls, except for slightly retarded growth at the higher dose.

Teratology studies in mice and rats, at oral doses of 2, 3, 10, and 20 mg/kg/day, showed no teratogenic effects on fetuses. At the higher doses, pronounced gastrointestinal effects were observed in the dams and a marked toxic effect noted in fetuses (reduced birth weights and increased fetal death).

Pregnant rabbits, treated with an oral dose of 5 or 10 mg/animal/day throughout the gestation period, showed a dose-dependent increase in resorption rate, diminished fetus weight, and abnormal skeletal findings. Definite embryo toxicity was observed at the highest dose although there was no evidence to suggest teratogenicity.

#### Dimethyl sulfoxide (DMSO)

Studies show that for induction of a teratogenic effect in mammals, very high doses (2,500 - 10,000 mg/kg) of DMSO must be administered systemically, not topically.

## **17 SUPPORTING PRODUCT MONOGRAPHS**

1. PrPENNSAID® (Diclofenac Sodium Solution) 1.5% w/w, submission control 255809; Product Monograph, Paladin Labs Inc., February 16, 2022.

## PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### **TARO-DICLOFENAC**

#### **Diclofenac sodium topical solution**

Read this carefully before you start taking **TARO-DICLOFENAC** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **TARO-DICLOFENAC**.

#### **Serious Warnings and Precautions**

##### **Risk of Heart and Blood Vessel Problems:**

Using non-steroidal anti-inflammatory drugs (NSAIDs), like TARO-DICLOFENAC, can cause heart and blood vessel problems like heart attack, stroke, blood clots, high blood pressure and heart failure. These can lead to death.

The risk of having heart problems is higher if you use TARO-DICLOFENAC for longer periods of time and/or in people who have heart disease.

Tell your healthcare professional if you have heart problems, high blood pressure or diabetes.

##### **Risk of Stomach and Intestine (Gastrointestinal) Problems:**

Using NSAIDs, like TARO-DICLOFENAC, can cause stomach and intestine problems like ulcers, inflammation, bleeding, holes/perforation, blockage or pain.

**Talk to your healthcare professional about any medical conditions you have and any drugs you are taking.**

##### **Pregnancy:**

Do **NOT** use TARO-DICLOFENAC if you are pregnant.

Medicines like TARO-DICLOFENAC may cause harm to your unborn baby.

Tell your healthcare professional right away if you become pregnant, think you may be pregnant or want to get pregnant while you are using TARO-DICLOFENAC.

#### **What is TARO-DICLOFENAC used for?**

TARO-DICLOFENAC is used in adults to treat the signs and symptoms of osteoarthritis in the knee(s). It helps relieve pain, swelling and stiffness.

#### **How does TARO-DICLOFENAC work?**

TARO-DICLOFENAC belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It is used topically (on the skin) to reduce the chemicals produced by your body which cause pain and swelling.

TARO-DICLOFENAC only treats the symptoms and relieves pain and inflammation as long as you use it. TARO-DICLOFENAC does not cure your arthritis or stops it from getting worse.



## **What are the ingredients in TARO-DICLOFENAC?**

Medicinal ingredients: diclofenac sodium

Non-medicinal ingredients: dimethyl sulfoxide, ethanol, glycerin, propylene glycol, purified water.

## **TARO-DICLOFENAC comes in the following dosage forms:**

**Topical solution:** 1.5% w/w

### **Do not use TARO-DICLOFENAC if you:**

- are planning to have or have recently had heart bypass surgery
- have severe, uncontrolled heart failure
- have active stomach or intestinal ulcers
- have inflammatory bowel disease (Crohn's disease or Ulcerative Colitis)
- are allergic to diclofenac sodium, or to any of the non-medicinal ingredients in TARO-DICLOFENAC or component of the container (see **What are the ingredients in TARO-DICLOFENAC?**)
- have a history of asthma, hives, growths in your nose, sinus swelling or symptoms of an allergic reaction after taking acetylsalicylic acid (ASA) or other NSAIDs
- have liver disease (active or severe)
- have kidney disease (severe or worsening)
- have high levels of potassium in your blood
- are using other NSAIDs
- are under 18 years of age
- have been prescribed TARO-DICLOFENAC for longer than 3 months, TARO-DICLOFENAC cannot be used longer than 3 months
- are pregnant or breastfeeding

### **To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TARO-DICLOFENAC. Talk about any health conditions or problems you may have, including if you:**

- have or have had a heart attack, chest pain, heart disease, stroke or heart failure
- have asthma
- have a stomach infection
- have a history of ulcer or bleeding from the stomach or gut (small or large intestines)
- have other bleeding or blood problems
- have liver or kidney problems, urine problems or are dehydrated
- have high blood pressure, high cholesterol or diabetes
- have poor blood flow to your extremities (like your hands and feet)
- smoke or used to smoke

drink a lot of alcohol  
are planning on becoming pregnant. TARO-DICLOFENAC cannot be used if you are pregnant  
are planning to breastfeed, TARO-DICLOFENAC cannot be used if you are breastfeeding  
have immune system problems

**Other warnings you should know about:**

**Serious Skin Reactions:** In rare cases, serious or life-threatening skin reactions listed below have been reported with some NSAIDs, such as TARO-DICLOFENAC.

drug reaction with eosinophilia and systemic symptoms (DRESS),  
Stevens-Johnson syndrome (SJS),  
toxic epidermal necrolysis (TEN),  
exfoliative dermatitis and  
erythema multiforme

**You may be at a greater risk of experiencing a serious skin reaction during the first month of treatment.**

See the **Serious side effects and what to do about them table**, below, for more information on these and other serious side effects.

**TARO-DICLOFENAC** might cause you to become more sensitive to sunlight. Sunlight or sunlamps may cause sunburn, skin blisters, skin rashes, redness, itching and discoloration or vision changes. If you have a reaction from the sun, talk to your healthcare professional.

**Check-ups and Testing:** You should have regular visits with your healthcare professional while you are using TARO-DICLOFENAC to monitor your health. They should:

Check your blood pressure.  
Check your eyes. TARO-DICLOFENAC can cause blurred or reduced vision.  
Do blood and urine tests to check your liver, kidney and blood health.

**Surgery:** Tell any doctor, dentist, pharmacist or healthcare professional that you see, that you are using this medicine. This is especially important if you are planning to have heart surgery.

**Driving and Using Machines:** Be careful about driving or doing activities that require you to be alert, as TARO-DICLOFENAC may affect your vision or nervous system. If you become drowsy, dizzy or light-headed after using TARO-DICLOFENAC, do NOT drive or operate machinery.

**Adults (65 years or older):** Side effects like gastrointestinal problems may happen more often. Your healthcare professional might have you start with a lower dose of TARO-DICLOFENAC. They will monitor your health during and after treatment.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with TARO-DICLOFENAC:**

acetylsalicylic acid (ASA) or other NSAIDs, used to treat pain, fever and inflammation, such as celecoxib, diclofenac, ibuprofen, naproxen  
digoxin, used for heart problems  
medicines used as blood thinners or to prevent blood clots, such as heparin, warfarin, ASA, clopidogrel  
oral medicines used to treat diabetes  
medicines used to lower extra fluid levels (diuretics), such as furosemide, hydrochlorothiazide  
medicines used to lower blood pressure  
corticosteroids used as an anti-inflammatory, such as glucocorticoids, like prednisone  
methotrexate, used to treat some cancers or arthritis  
acetaminophen, used to treat pain and fevers  
cyclosporine, used to lower the risk of organ rejection  
lithium, used to treat bipolar disorder  
medicines used to treat gout, such as probenecid and sulfinpyrazone  
antibiotics used to treat bacterial infections, such as quinolone  
phenytoin, used to treat seizures  
voriconazole, used to treat infections\  
alcohol

**How to take TARO-DICLOFENAC:**

Use TARO-DICLOFENAC exactly how your healthcare professional has told you to. Talk to your healthcare professional if you are unsure.  
Do not stop using TARO-DICLOFENAC or change your dose without talking to your healthcare professional.  
TARO-DICLOFENAC is for **external use only**. Avoid contact with your eyes and mucous membranes.  
Apply TARO-DICLOFENAC to clean, dry skin.  
Do not use TARO-DICLOFENAC under bandages or dressings.  
Do not apply TARO-DICLOFENAC to open, broken or infected skin.  
Do not apply any other medication to the treated area  
Do not use TARO-DICLOFENAC for longer than 3 months.

**Usual dose:**

**Adults 18 years and older:** Apply 40 drops to affected knee only, 4 times a day, or 50 drops, 3 times a day.

## How to Apply TARO-DICLOFENAC:

Use the plastic dropper to dispense 10 drops of TARO-DICLOFENAC into your hand, or directly onto your affected knee.

Spread TARO-DICLOFENAC evenly around the front, back and sides of your knee.

Repeat these steps until you have applied the prescribed amount of TARO-DICLOFENAC (either 40 or 50 drops) and your knee is completely covered.

If you are using TARO-DICLOFENAC on both your knees, repeat the above steps to treat your other knee.

Wash your hands when you are finished using TARO-DICLOFENAC.

Allow several minutes for TARO-DICLOFENAC to dry.

## Overdose:

If you think you, or a person you are caring for, have taken too much TARO-DICLOFENAC, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

## Missed Dose:

If you miss applying a dose of TARO-DICLOFENAC, skip the missed dose. Then continue with your next dose at the usual time. Do not double the next dose to make up for a missed dose.

## What are possible side effects from using TARO-DICLOFENAC?

These are not all the possible side effects you may have when taking TARO-DICLOFENAC. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- confusion, dizziness, light-headedness, spinning
- diarrhea, constipation
- feeling gassy
- feeling of burning/prickliness/numbing
- hair loss
- hard to concentrate or think
- headache
- heartburn, indigestion
- irritation on the skin where you apply TARO-DICLOFENAC including rash, itchiness, dryness, tingling
- mouth sores
- muscle pain
- nervousness
- skin rash
- sore throat
- stomach upset/abdominal pain
- taste disorder, thirst, dry mouth
- vomiting, nausea

| Serious side effects and what to do about them  |                                      |              |   |
|---|--------------------------------------|--------------|---|
| Symptom / effect  | Talk to your healthcare professional |              | Stop taking drug and get immediate medical help |
|   | Only if severe                       | In all cases |   |
| <b>RARE</b>   |                                      |              |   |
| <b>Serious Skin Reactions:</b> fever, severe rash, swollen lymph glands, flu-like feeling, blisters and peeling skin that may start in and around the mouth, nose, eyes and genitals and spread to other areas of the body, swelling of face and/or legs, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, feeling thirsty, urinating less often, less urine or dark urine. |                                      |              | ✓   |
| <b>UNKNOWN</b>  |                                      |              |   |
| <b>Allergic Reaction:</b> rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing   |                                      |              | ✓   |
| <b>Aseptic Meningitis (Inflammation of the protective lining of the brain that is not caused by infection):</b> headaches, stiff neck, nausea, vomiting, fever, clouding of consciousness   |                                      | ✓            |   |
| <b>Blood Clots:</b><br><b>In the leg or arm:</b> pain, redness and swelling, skin is warm to the touch<br><b>In the lung:</b> chest pain, usually worse with breathing, shortness of breath, cough that may contain blood, dizziness, loss of consciousness   |                                      |              | ✓   |
| <b>Blood Problems (low white and/or red blood cell or platelet count):</b> feeling tired or weak, pale skin, bruising or bleeding for longer than usual if you hurt yourself, fever, chills   |                                      | ✓            |   |

| Serious side effects and what to do about them   |                                      |              |   |
|--|--------------------------------------|--------------|---|
| Symptom / effect   | Talk to your healthcare professional |              | Stop taking drug and get immediate medical help |
|  | Only if severe                       | In all cases |   |
| <b>Congestive Heart Failure (heart does not pump blood as well as it should):</b> shortness of breath, fatigue and weakness, swelling in ankles, legs and feet, cough, fluid retention, lack of appetite, nausea, rapid or irregular heartbeat, reduced ability to exercise                            |                                      |              | ✓   |
| <b>Depression (sad mood that will not go away):</b> difficulty sleeping or sleeping too much, changes in appetite or weight, reduced sex drive and thoughts of death or suicide  |                                      | ✓            |   |
| <b>Gastrointestinal (GI) Problems (bleeding, blockage, holes, ulcers or inflammation in your GI tract):</b> blood in vomit, black tarry or bloody stool, dizziness, stomach pain, bloating, loss of appetite, weight loss, nausea, vomiting, constipation or diarrhea, chills or fever                 |                                      | ✓            |   |
| <b>Hypertension (high blood pressure):</b> fatigue, dizziness or fainting, chest pain  | ✓                                    |              |   |
| <b>Liver Problems:</b> yellowing of the skin or eyes (jaundice), right upper stomach pain or swelling, nausea or vomiting, unusual dark urine, unusual tiredness   |                                      | ✓            |   |
| <b>Lung Problems, Asthma:</b> increased shortness of breath, wheezing, difficulty breathing, cough and chest tightness, irregular heartbeat  |                                      |              | ✓   |
| <b>Myocardial Infarction (heart attack):</b> pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint, possible irregular heartbeat |                                      |              | ✓   |

| Serious side effects and what to do about them   |                                      |              |   |
|--|--------------------------------------|--------------|---|
| Symptom / effect   | Talk to your healthcare professional |              | Stop taking drug and get immediate medical help |
|  | Only if severe                       | In all cases |   |
| <b>Stroke (bleeding or blood clot in the brain):</b> sudden numbness, weakness or tingling of the face, arm or leg, particularly on one side of the body, sudden headache, blurry vision, difficulty swallowing or speaking, lethargy, dizziness, fainting, vomiting, trouble understanding, trouble with walking, loss of balance |                                      |              | ✓   |

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

Visiting the Web page on Adverse Reaction Reporting

(<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on

how to report online, by mail or by fax; or

Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### Storage:

Store at room temperature (15-25 °C).

Store upright

Do not keep outdated medicine or medicine no longer needed.

Keep out of reach and sight of children.

### If you want more information about TARO-DICLOFENAC:

Talk to your healthcare professional

Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website:

(<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [www.taro.com](http://www.taro.com), or by calling 1-800-268-1975.

This leaflet was prepared by Taro Pharmaceuticals Inc.

Last Revised: April 5, 2023